Abstract:Central MessageAlthough the debate on the choice of surgery or SBRT for early NSCLC is an old topic, it has new content, such as a smaller resection scope of surgery, the new GGO issues, and the concept of MRD.See Article page 249. Although the debate on the choice of surgery or SBRT for early NSCLC is an old topic, it has new content, such as a smaller resection scope of surgery, the new GGO issues, and the concept of MRD. See Article page 249. Since the successful surgical treatment of lung cancer in the prior century, surgery has been the gold standard for treatment of early lung cancer. The concept of surgery seems unchanged, yet now there are many new theories (oncology), new knowledge, and new technologies (oncology and surgery). Thus, the connotation of surgery has changed greatly. Stereotactic body radiation therapy (SBRT) is an alternative to surgery for the treatment of early non–small cell lung cancer (NSCLC). SBRT can also provide favorable effect of local control, which poses a challenge to surgery in treating early NSCLC. However, the relative advantages and disadvantages of SBRT and surgery are still controversial. In 2015, Chang and colleagues1Chang J.Y. Senan S. Paul M.A. Mehran R.J. Louie A.V. Balter P. et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Oncol. 2015; 16 (Erratum in: Lancet Oncol. 2015;16:e427): 630-637Abstract Full Text Full Text PDF PubMed Scopus (955) Google Scholar analyzed the data of 2 incomplete studies (STARS and ROSEL) and found that SBRT brought longer recurrence-free survival for stage I NSCLC with tumor diameter less than 4 cm; this report pushed the debate to a new height. At the same time, several retrospective studies performed by surgeons suggested that surgery was more effective. Obviously, the retrospective study by Littau and colleagues2Littau M.J. Freeman R. Vigneswaran W.T. Luchette F.A. Baker M.S. Raad W. et al.Comparative effectiveness of stereotactic body radiation therapy versus surgery for stage I lung cancer in otherwise healthy patients: an instrumental variable analysis.J Thorac Cardiovasc Surg Open. 2022; 9: 249-261Scopus (2) Google Scholar also supported surgery, and the sample size was larger with more advanced statistical methods. The authors compared the efficacies of SBRT and surgery for patients with clinical stage I NSCLC who were treated between 2004 and 2016. Of the 26,080 eligible patients, 5465 received SBRT. The results showed that surgery had better efficacy for stage I NSCLC. The core of this topic is, after all, the oncological effect, whereas these studies were still based on the slightly old and single concept of anatomic “early lung cancer.” In fact, there are many new data on the surgical treatment of early NSCLC that were not considered in previous studies. Since 1995, lobectomy has been the standard of surgical resection for early NSCLC. In 2021 at the 101st annual meeting of the American Association for Thoracic Surgery, Asamura and colleagues3Asamura H, Okada M, Saji H, Tsuboi M, Nakajima R, Suzuki K, et al. Randomized trial of segmentectomy compared to lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). 101st AATS conference. Oral presentation. Seattle, USA. April 30-May 2, 2021.Google Scholar presented results of the long-awaited Japan Clinical Oncology Group (JCOG) 0802 study. The study compared the efficacies of segmentectomy and lobectomy in the treatment of peripheral NSCLC with tumor diameter 2 cm or less and consolidation/tumor ratio (CTR) 0.5 or greater. The primary end point was overall survival (OS), and secondary end points were postoperative pulmonary function, relapse-free survival, and rate of local recurrence. The study enrolled 1106 patients, of whom 554 underwent lobectomy and 552 underwent segmentectomy. There were 968 adenocarcinomas, including 923 patients with pathologically stage IA, and the mean diameter of the tumors was 1.6 cm (0.6-2.0 cm). There were 553 patients with CTR of 1. The median follow-up was 7.3 years. The 5-year OS after segmentectomy and lobectomy were 94.3% and 91.1%, respectively (hazard ratio, 0.663, 95% confidence interval, 0.474-0.927). The 5-year relapse-free survival between the 2 groups was not statistically different, being 88% and 87.9%, respectively. Compared with lobectomy, the death risk after segmentectomy reduced by 34%. The median decline rates of forced expiratory volume in the first second, 6 months and 1 year after segmentectomy were significantly better compared with that after lobectomy, namely, 10.4% versus 13.1% and 8.5% versus 12.0%, respectively. JCOG 0802 was the first phase III clinical trial that proved segmentectomy was statistically superior to lobectomy in the treatment of early-stage NSCLC in terms of OS and pulmonary function. The study also indicated that for peripheral NSCLC with tumor diameter 2 cm or less and CTR greater than 0.5, segmentectomy should be the standard treatment method. On the basis of the results of JCOG 0802, Japanese scholars are performing a prospective study on segmentectomy and large wedge resection in the same patient group that was examined in JCOG 0802 (tumor ≤2 cm, CTR >0.5)4Shimoyama R. Tsutani Y. Wakabayashi M. Katayama H. Fukuda H. Suzuki K. et al.A multi-institutional randomized phase III trial comparing anatomical segmentectomy and wedge resection for clinical stage IA non-small cell lung cancer in high-risk operable patients: Japan Clinical Oncology Group Study JCOG1909 (ANSWER study).Jpn J Clin Oncol. 2020; 50: 1209-1213https://doi.org/10.1093/jjco/hyaa107Crossref PubMed Scopus (3) Google Scholar and a repeat JCOG 0802 study of patients with 2- to 3-cm diameter tumors and CTR greater than 0.5. These studies indicate that the scope of surgery for early-stage NSCLC may be decreasing. In this context, it is not surprising that there is a local control method without surgery such as SBRT, and the results of the study by Chang and colleagues1Chang J.Y. Senan S. Paul M.A. Mehran R.J. Louie A.V. Balter P. et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Oncol. 2015; 16 (Erratum in: Lancet Oncol. 2015;16:e427): 630-637Abstract Full Text Full Text PDF PubMed Scopus (955) Google Scholar are not surprising. There will still be room for debate on the choice of surgery or SBRT for the treatment of early NSCLC. The concept of ground-glass opacity (GGO) appeared with the advent of high-resolution CT. GGO is not only a new imaging concept but also a new clinical issue. According to the prognosis and follow-up results of GGO, the 8th TNM staging system and new classification of adenocarcinoma by the World Health Organization in 2015 clearly stated that the diameter of pure GGO and heterogeneous GGO with a diameter 3 cm or less should not be calculated in the T stages of the patients.5Travis W.D. Brambilla E. Nicholson A.G. Yatabe Y. Austin J.H.M. Beasley M.B. et al.The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.J Thorac Oncol. 2015; 10: 1243-1260Abstract Full Text Full Text PDF PubMed Scopus (2216) Google Scholar The measurement of T descriptor for semi-solid GGO is according to the solid component of the tumor. Therefore, pure GGO with a diameter 3 cm or less is not classified as T1a, but it belongs to carcinoma in situ. Histopathology has always been the only gold standard to decide the nature of a tumor, determine the treatment plan, and predict prognosis. However, with progress and deeper understanding of GGO-like lung adenocarcinoma, the black and white thinking of tumor histopathology has been challenged in the diagnosis of GGO-like lung adenocarcinoma; the clinician needs multidimensional indicators to judge the malignant behavior of GGO-like lung adenocarcinoma. Therefore, the 2011 multidisciplinary classification of pulmonary adenocarcinoma,6Travis W.D. Brambilla E. Noguchi M. Nicholson A.G. Geisinger K.R. Yatabe Y. et al.International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma.J Thorac Oncol. 2011; 6: 244-285Abstract Full Text Full Text PDF PubMed Scopus (3375) Google Scholar accepted by the World Health Organization in 2015, has excellently demonstrated the advantages of a multidisciplinary perspective. This histopathological classification based on multidisciplinary discussion is the first new classification of lung adenocarcinoma in the history of lung cancer pathology. The disciplines involved in the discussion included pathologists, imaging physicians, surgeons, respiratory disease experts, molecular biologists, and oncologists. The multidisciplinary approach has changed from “differentiation degree” of lung adenocarcinoma to “growth pattern,” including precursor lesions, carcinoma in situ, minimally invasive adenocarcinoma, invasive adenocarcinoma, and variants of invasive adenocarcinoma. The pathology experts have associated each growth pattern with a specific degree of malignancy. More important, the new classification compares, under the microscope, the possible imaging manifestations for each growth pattern, it emphasizes the weight of imaging manifestations in judging the malignant biological behavior and prognosis of GGO-like lung adenocarcinoma. Again, it points out the importance of solid components in reflecting the malignant biological behavior of tumors, which is a great progress of lung cancer in recent years. Unfortunately, in the real world of clinical practice, some clinicians still do not fully understand the work of experts in multidisciplinary pathological classification. Instead, clinicians instinctively, consistently, and solely rely on the pathological reports to determine treatment strategies, neglecting the importance of multidisciplinary factors outside the microscope, especially the imaging in tumor malignant biology and prognosis. The results of JCOG02017Suzuki K. Koike T. Asakawa T. Kusumoto M. Asamura H. Nagai K. et al.Japan Lung Cancer Surgical Study Group (JCOG LCSSG)A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201).J Thorac Oncol. 2011; 6: 751-756https://doi.org/10.1097/JTO.0b013e31821038abAbstract Full Text Full Text PDF PubMed Scopus (359) Google Scholar showed that if the pulmonary tumors with a diameter 3 cm or less have a GGO component, the 5-year OS could be 90% or greater regardless of the T staging, and the tumor diameter only influences the survival of patients with solid tumors. The JCOG0201 investigators concluded that the index with best specificity to predict the microscopic histopathology of noninvasive lung adenocarcinoma was CTR. The specificity of tumor diameter 2 cm or less and CTR 0.25 or less in predicting pathological noninvasive lung adenocarcinoma was 97.5%. Although most scholars still use the microscope to determine whether a pulmonary tumor is invasive adenocarcinoma, the imaging findings seem to better reflect the infiltration at the level of clinical outcome. In a sense, the subtext of the new classification of multidisciplinary lung adenocarcinoma is if the pure GGO with a diameter of 3 cm or less was diagnosed under thin-layer, high-resolution, and standard-dose CT. Regardless of the growth pattern of the tumor under the microscope, it should be regarded as carcinoma in situ to avoid overtreatment caused by overdiagnosis and overstaging. Moreover, the results of JCOG 08048Suzuki K. Watanabe S.I. Wakabayashi M. Saji H. Aokage K. Moriya Y. et al.A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer.J Thorac Cardiovasc Surg. November 12, 2020; ([Epub ahead of print])https://doi.org/10.1016/j.jtcvs.2020.09.146Abstract Full Text Full Text PDF Scopus (28) Google Scholar implied that when a tumor of GGO-like lung cancer was peripheral, then anatomic resection was not necessary, and wedge resection with a 5-mm margin could cure patients. Therefore, the GGO component is an independent favorable prognostic factor for early-stage NSCLC. Surgeons often criticized the data of STARS and ROSEL for the poor quality of their surgical group (44% of grade 3-4 postoperative complication rate), which may have led directly to the results of Chang and colleagues.1Chang J.Y. Senan S. Paul M.A. Mehran R.J. Louie A.V. Balter P. et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Oncol. 2015; 16 (Erratum in: Lancet Oncol. 2015;16:e427): 630-637Abstract Full Text Full Text PDF PubMed Scopus (955) Google Scholar As in surgery, the technical level of radiotherapy will also directly affect the prognosis of patients. Therefore, any comparative study of SBRT and surgery needs to balance the completion quality of the 2 treatment groups, which requires more data and, at least, data for the complications related to the 2 treatments. The NCDB database has the following drawbacks: 1. The inherent confounding variables of retrospective analysis cannot be avoided. Therefore, it is impossible to assess the relationship between OS and disease-specific survival after surgery. 2. Whether the results showed that surgery is better than SBRT or SBRT is better than surgery, possible selection bias could not be excluded. Although the study by Littau and colleagues2Littau M.J. Freeman R. Vigneswaran W.T. Luchette F.A. Baker M.S. Raad W. et al.Comparative effectiveness of stereotactic body radiation therapy versus surgery for stage I lung cancer in otherwise healthy patients: an instrumental variable analysis.J Thorac Cardiovasc Surg Open. 2022; 9: 249-261Scopus (2) Google Scholar excluded patients with comorbidities, patients in the surgical group may have been healthier. 3. The sample size of the SBRT group was small, the efficiency of research and analysis may have been insufficient, and there may have been type II errors. 4. There were many missing or incomplete data in both NCDB and Surveillance Epidemiology and End Results databases: (1) There were data that the authors could not confirm, such as the staging and treatment methods; (2) Because the pathological tissues could not be reevaluated, there was a lack of imaging and pathological review of patients and an absence of key pathological variables, such as margin status, lymphatic or vascular infiltration, resection completeness, and lymph node dissection extent. (3) NCDB and Surveillance Epidemiology and End Results databases do not include information on chemotherapy regimen, drugs, doses, and toxicities; (4) Although there are approximate anatomic targets of radiotherapy, there is a lack of information for further specific types of radiotherapy. (5) There is no information in the database about recurrence, so it is difficult to analyze the recurrence pattern. (6) There is a lack of preoperative evaluation information, such as general physical condition, weight loss, smoking status, and cardiopulmonary function (echocardiography and pulmonary function). Therefore, it is impossible to assess the true reason for sub-lobectomy. Even after curative surgery, a considerable proportion of patients with early NSCLC die of recurrence and metastasis. Recently, the concept of minimal residual disease (MRD) has attracted attention. MRD refers to the molecular abnormalities of cancer origin that cannot be found by traditional imaging (including positron emission tomography/computed tomography) or laboratory methods after treatment, but found by liquid biopsy, which represents the possibility of the persistence and clinical progress of lung cancer. Currently, the most common indicator for MRD is circulating tumor DNA.9Chae Y.K. Oh M.S. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.J Thorac Oncol. 2019; 14: 16-24https://doi.org/10.1016/j.jtho.2018.09.022Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar Molecular abnormalities of lung cancer refer to the stable detection of circulating tumor DNA with 0.02% or greater in peripheral blood, including lung cancer driver genes or other class I/II gene variants.10Newman A.M. Bratman S.V. To J. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Nat Med. 2014; 20: 548-554https://doi.org/10.1038/nm.3519Crossref PubMed Scopus (1302) Google Scholar The basic technology of MRD includes tumor-informed assays, an NGS panel, and tumor agnostic assays. However, these technologies are in the exploratory stage, and prospective studies are needed to determine their sensitivity, specificity, and predictive value. The possible use of MRD in early NSCLC is that a positive MRD after curative resection indicates a high risk of recurrence that requires follow-up management. MRD monitoring is recommended every 3 to 6 months postoperatively. Perioperative clinical trials of resectable NSCLC based on MRD are recommended and provide accurate perioperative treatment as much as possible. The activity of MRD in driver gene-positive and driver gene-negative patients should be evaluated. However, all of these are in the phase of clinical research and have not yet entered clinical practice. Although the debate on the choice of surgery or SBRT for early NSCLC is an old topic, it has new content, such as a smaller resection scope of surgery, the new GGO issues, and the concept of MRD. All these factors will affect the choice of treatment for early NSCLC. Comparative effectiveness of stereotactic body radiation therapy versus surgery for stage I lung cancer in otherwise healthy patients: An instrumental variable analysisJTCVS OpenVol. 9PreviewStereotactic body radiation therapy (SBRT) is an established primary treatment modality in patients with lung cancer who have multiple comorbidities and/or advanced-stage disease. However, its role in otherwise healthy patients with stage I lung cancer is unclear. In this context, we compared the effectiveness of SBRT versus surgery on overall survival using a national database. Full-Text PDF Open Access

Abstract:Central MessageLimiting surgery, enhancing comprehensive treatment, and implementing strategies to prevent nosocomial COVID-19 infection will ensure medical safety and quality of care. Limiting surgery, enhancing comprehensive treatment, and implementing strategies to prevent nosocomial COVID-19 infection will ensure medical safety and quality of care. At present, Coronavirus Disease 2019 (COVID-19) is raging worldwide, and almost all thoracic surgeons are facing unprecedented challenges. In this special period, how can we treat patients with thoracic disease safely and, particularly, how can we perform thoracic surgery safely? In addition, how do we prevent COVID-19 infection in the hospital and protect medical personnel? Other questions we must answer are whether patients are more susceptible to COVID-19 after thoracic surgery and what are the clinical manifestations and outcomes of infected postoperative patients. Faced with the global public health issue of COVID-19, every medical worker is responsible and obligated to share experiences and lessons in a timely manner to help humans through the present difficulties. Therefore, we strongly support our colleagues from China in their effort to share their experiences and lessons from combating COVID-19. Peng and colleagues1Peng S. Huang L. Zhao B. Zhou S. Braithwaite I. Zhang N. et al.Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.J Thorac Cardiovasc Surg. 2020; 160: 585-592.e2Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar performed a cohort study from the area with a global high incidence of COVID-19, which has important reference value for guiding the daily work of thoracic surgery in the current environment of COVID-19. Peng and colleagues1Peng S. Huang L. Zhao B. Zhou S. Braithwaite I. Zhang N. et al.Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.J Thorac Cardiovasc Surg. 2020; 160: 585-592.e2Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar reported their experience of 11 patients infected with COVID-19 after thoracic surgery in a high-volume center in China during the pandemic. There were 205 patients admitted, including 119 cases with surgery and 86 cases without surgery. After surgery, 11 patients and 8 medical workers were infected with COVID-19.2Li Y.K. Peng S. Li L.Q. Wang Q. Ping W. Zhang N. et al.Clinical and transmission characteristics of Covid-19—a retrospective study of 25 cases from a single thoracic surgery department.Curr Med Sci. 2020; 40: 295-300Crossref PubMed Scopus (155) Google Scholar The investigators analyzed the clinical symptoms, laboratory tests, imaging manifestations, and treatment outcomes of these patients. The mortality of infected patients after thoracic surgery was 27.3%, which was 10 times higher than the usual 2% mortality3Allen M.S. Darling G.E. Pechet T.T. Mitchell J.D. Herndon II, J.E. Landreneau R.J. et al.Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.Ann Thorac Surg. 2006; 81: 1013-1020Abstract Full Text Full Text PDF PubMed Scopus (577) Google Scholar and higher than the 4.3% mortality of COVID-19–infected cases without surgery according to another report.4Wang D. Hu B. Hu C. Zhu F. Liu X. Zhang J. et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020; 323: 1061-1069Crossref PubMed Scopus (16387) Google Scholar On the basis of these data, we must adjust our daily work to meet the current challenges. Although the risk levels vary from region to region, and the measures taken are also different, it is difficult for one recommendation to cover the scope of all medical centers. Nevertheless, the recommendations we are proposing should have certain reference value and warning function to thoracic surgeons from different regions. The World Health Organization has declared COVID-19 a global health concern and pandemic. Because the economic development, medical resources, and clinical practice of different regions are not the same, "universal precaution" could have a different context while the concept remains the same. This point is important; thus, we suggest that all patients who come to the hospital for surgery be treated under the "universal precaution" principle on the premise of enough supplies, particularly in the center of the epidemic. Studies also show that many asymptomatic patients are infectious, and their infectivity is no less than that of symptomatic patients.5Bai Y. Yao L. Wei T. Tian F. Jin D.Y. Chen L. et al.Presumed asymptomatic carrier transmission of COVID-19.JAMA. 2020; 323: 1406-1407Crossref PubMed Scopus (3099) Google Scholar In addition, there is the possibility for sudden acceleration of infection. Therefore, a simple inquiry about fever, cough, and shortness of breath in the past 2 weeks and any history of recent wildlife contact cannot help us identify problematic patients.6Qiu J. Covert coronavirus infections could be seeding new outbreaks.Nature. March 20, 2020; ([Epub ahead of print])Crossref Scopus (156) Google Scholar It is more reasonable to use universal precaution for COVID-19 screening of every new patient. Although Peng and colleagues1Peng S. Huang L. Zhao B. Zhou S. Braithwaite I. Zhang N. et al.Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.J Thorac Cardiovasc Surg. 2020; 160: 585-592.e2Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar did not provide detailed information about the specific diseases of the 119 surgical patients, evaluating ground-glass opacities (GGOs) seen on chest computed tomography (CT) scans has become an important part of clinical practice of some, perhaps many, thoracic surgery teams in China. Numerous studies have proved that the incidence of lung adenocarcinoma presented as GGO on CT is increasing recently. Some clinical features and biological behaviors of this kind of tumor are different from the traditional lung adenocarcinoma presented as solid nodules on imaging. For example, studies showed that GGO-like lung adenocarcinoma is more common in Asian and young women than in the traditional high-risk population with lung cancer, such as senior men and smokers.7Zhang Y. Jheon S. Li H. et al.Results of low-dose computed tomography as a regular health examination among Chinese hospital employees.J Thorac Cardiovasc Surg. November 14, 2019; ([Epub ahead of print])Abstract Full Text Full Text PDF Scopus (82) Google Scholar, 8Chen K.N. Commentary: pay attention to low-risk populations for lung cancer, but cautiously interpret ground-glass nodules screened by low-dose computed tomography scan.J Thorac Cardiovasc Surg. November 27, 2019; ([Epub ahead of print])Abstract Full Text Full Text PDF Scopus (3) Google Scholar, 9Chen K.N. The diagnosis and treatment of lung cancer presented as ground-glass nodule.Gen Thorac Cardiovasc Surg. December 10, 2019; ([Epub ahead of print])Crossref Scopus (21) Google Scholar Different from conventional solid lung adenocarcinomas, this special type of lung adenocarcinoma, which emerged 20 years ago, exhibits indolent growth as its most obvious feature.10Detterbeck F.C. Achieving clarity about lung cancer and opacities.Chest. 2017; 151: 252-254Abstract Full Text Full Text PDF PubMed Scopus (17) Google Scholar Moreover, the pure GGO lung adenocarcinoma as screened by low-dose CT in an asymptomatic population grows even more slowly. In the 8th edition TNM staging system, it is classified as c0 stage. For semi-solid GGO, T is calculated on the basis of the diameter of the solid component of the tumor.11Travis W.D. Asamura H. Bankier A.A. Beasley M.B. Detterbeck F. Flieder D.B. et al.The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming Eighth Edition of the TNM classification of lung cancer.J Thorac Oncol. 2016; 11: 1204-1223Abstract Full Text Full Text PDF PubMed Scopus (534) Google Scholar In addition, data support the conclusion that the GGO component is a favorable prognostic factor for lung adenocarcinoma.8Chen K.N. Commentary: pay attention to low-risk populations for lung cancer, but cautiously interpret ground-glass nodules screened by low-dose computed tomography scan.J Thorac Cardiovasc Surg. November 27, 2019; ([Epub ahead of print])Abstract Full Text Full Text PDF Scopus (3) Google Scholar,9Chen K.N. The diagnosis and treatment of lung cancer presented as ground-glass nodule.Gen Thorac Cardiovasc Surg. December 10, 2019; ([Epub ahead of print])Crossref Scopus (21) Google Scholar Coincidentally, the early imaging manifestation of COVID-19 is also predominantly ground-glass shadow.1Peng S. Huang L. Zhao B. Zhou S. Braithwaite I. Zhang N. et al.Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.J Thorac Cardiovasc Surg. 2020; 160: 585-592.e2Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar Although there are some distinguishing features with GGO-like lung adenocarcinoma, it is still necessary to attach great importance to possible misdiagnosis. In view of the indolence and relatively good prognosis of GGO-like lung adenocarcinoma, in the current environment of COVID-19 pandemic, we call for the cessation of all thoracic surgeries for GGO-like lung adenocarcinoma with a diameter of less than 30 mm during the COVID-19 pandemic.12Suzuki S. Sakurai H. Yotsukura M. Masai K. Asakura K. Nakagawa K. et al.Clinical features of ground glass opacity-dominant lung cancer exceeding 3.0 cm in the whole tumor size.Ann Thorac Surg. 2018; 105: 1499-1506Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar Of course, GGO-like lung adenocarcinoma should also be differentiated from other benign diseases to avoid the risk of infection caused by unnecessary surgery, such as ground-glass shadow caused by hemoptysis in the lung, radiation-induced pneumonia, exogenous lipid pneumonia, and immunotherapy-related pneumonitis. According to the survey of Rocco and colleagues13Rocco G. Nason K. Brunelli A. Varela G. Waddell T. Jones D.R. Management of stage IIIA (N2) non-small cell lung cancer: a transatlantic perspective.J Thorac Cardiovasc Surg. 2016; 151: 1235-1238Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar in Europe and North America, as well as the data of the ADJUVANT/CTONG1104 Study in China,14Zhong W.Z. Wang Q. Mao W.M. Xu S.T. Wu L. Shen Y. et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.Lancet Oncol. 2018; 19: 139-148Abstract Full Text Full Text PDF PubMed Scopus (430) Google Scholar there are large treatment strategy differences for IIIA-N2 locally advanced non–small cell lung cancer. Certainly, in patients in whom surgery may be indicated for IIIA-N2, surgery should follow preoperative chemotherapy for oncologic reasons15Martins R.G. D'Amico T.A. Loo Jr., B.W. Pinder-Schenck M. Borghaei H. Chaft J.E. et al.The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.J Natl Compr Canc Netw. 2012; 10: 599-613Crossref PubMed Scopus (63) Google Scholar and to delay the surgery beyond the window of the pandemic. Patients who might be considered marginal candidates for surgery might be treated with chemoradiation followed by immunotherapy, according to the PACIFIC trial,16Antonia S.J. Villegas A. Daniel D. Vicente D. Murakami S. Hui R. et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.N Engl J Med. 2017; 377: 1919-1929Crossref PubMed Scopus (3120) Google Scholar avoiding the risks of hospitalization during the pandemic without compromising treatment for cure. There was no statistically significant difference in overall survival between chemoradiotherapy alone versus chemoradiotherapy plus surgery.17Albain K.S. Swann R.S. Rusch V.W. Turrisi 3rd, A.T. Shepherd F.A. Smith C. et al.Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet. 2009; 374: 379-386Abstract Full Text Full Text PDF PubMed Scopus (1257) Google Scholar As well, during the COVID-19 pandemic, clinicians should rely to a greater extent on positron emission tomography for staging18Schmidt-Hansen M. Baldwin D.R. Hasler E. Zamora J. Abraira V. Roqué I Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.Cochrane Database Syst Rev. 2014; 2014: CD009519PubMed Google Scholar to replace invasive biopsies and reduce the chance of infection among medical workers. Conversely, esophageal cancer is an important disease in the clinical practice of thoracic surgery, and esophagectomy is the earliest and most important treatment method so far. In China, squamous cell carcinoma accounts for 90% of esophageal cancer,19Mao Y.S. Gao S.G. Wang Q. Shi X.T. Li Y. Gao W.J. et al.Analysis of a registry database for esophageal cancer from high-volume centers in China.Dis Esophagus. December 20, 2019; ([Epub ahead of print])Crossref Scopus (21) Google Scholar and 90% of these cancers show locally advanced disease at the first visit. There is strong clinical evidence that the long-term survival of patients with locally advanced esophageal cancer is significantly better with induction chemoradiation followed by surgery compared with up-front surgery.20Shapiro J. van Lanschot J.J.B. Hulshof M.C.C.M. van Hagen P. van Berge Henegouwen M.I. Wijnhoven B.P.L. et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.Lancet Oncol. 2015; 16: 1090-1098Abstract Full Text Full Text PDF PubMed Scopus (1801) Google Scholar,21Yang H. Liu H. Chen Y. Zhu C. Fang W. Yu Z. et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial.J Clin Oncol. 2018; 36: 2796-2803Crossref PubMed Scopus (559) Google Scholar However, in clinical practice in China, preoperative treatment of locally advanced esophageal cancer is not universal because of different understanding of multimodality treatments, a lack of multidisciplinary cooperation, and unbalanced deployment of radiation technology and equipment. Thus, postoperative adjuvant treatment accounts for more than 50% of the comprehensive treatment for esophageal cancer,22Chen K.-N. Commentary: esophageal squamous cell carcinoma: a disease requiring more research.J Thorac Cardiovasc Surg. 2020; 160: 553-554Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar which not only affects the long-term survival of patients but also places patients at risk of infection during the COVID-19 pandemic. Preoperative induction chemoradiotherapy improves the curative effect of surgery, and some scholars even question the role of surgery in comprehensive treatment of esophageal squamous cell carcinoma. These specialists concluded that overall survival after concurrent chemoradiation was not statistically different from survival after trimodality therapy; therefore, concurrent chemoradiation could replace surgery entirely.23Bedenne L. Michel P. Bouché O. Milan C. Mariette C. Conroy T. et al.Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.J Clin Oncol. 2007; 25: 1160-1168Crossref PubMed Scopus (1047) Google Scholar Although this viewpoint is controversial because of a lack of strong evidence, under the current COVID-19 pandemic situation, we should more strictly consider the indications for surgery. We should choose more conservative treatments for seniors, those with severe comorbidities, and those with advanced disease to decrease the risks associated with surgery under this special situation. Conversely, we have noticed that preoperative radiation dosage is a controversial issue in preoperative chemoradiation. In fact, the "curative" radiation dosage in Asian countries is similar to the "preoperative induction" radiation dosage in western countries. In this special period, we might as well give "curative" concurrent chemoradiotherapy (radiation dose similar to the Western preoperative dose) and consider surgery in a "salvage" situation after close observation and follow-up. We can and should try to avoid elective operations during the outbreak. However, we cannot avoid emergency surgery, even for individuals with confirmed or suspected COVID-19 infection. In these circumstances, all medical workers participating in the care of patients with confirmed or suspected COVID-19 infection need 3-level protection, including medical masks, protective clothing, goggles/protective masks, double gloves, shoe covers, and so forth. All staff who participated in the care of these patients should undergo medical observation for 14 days after surgery. Patients undergoing emergency surgery should remain isolated from the preoperative preparation stage to postoperative treatment, and they must wear masks at all time. For operations in the central areas with continuous outbreak of the epidemic, even for patients without confirmed or suspected infection, reverse transcription polymerase chain reaction of samples taken from upper nasopharyngeal swabs should be performed, and preoperative preparations should be made immediately before the operations. If the test result is negative, it is recommended that patients remain in an isolation ward, and a 3-level protection protocol should be adopted during the operations. For patients with a negative test result before surgery, after intubation, the lower respiratory tract secretions should be tested again. Surgery shall be performed in an independent negative pressure operating room, and the number of participants shall be limited. After entering the operating room, no one shall enter or leave arbitrarily. All supplies shall be in the charge of nurses outside the operating room. Intubation should be performed after anesthesia. A disposable filter should be arranged between the tracheal intubation and the respiratory tract to reduce contamination of the respiratory tract. More attention should be devoted to protection when suctioning sputum, and suction should be performed in a closed environment. During the operations, the use of energy devices and energy power should be reduced to limit aerosol caused by the devices. For examination, surgical specimens should be sealed in a double-layered bag. After surgery, the operating room should be disinfected thoroughly, and it can be reused only after passing a sampling test by the infection management department. Some patients undergoing elective surgery, but could not wait for too long because of the disease condition, should be observed in a transitional ward for 2 weeks. Two weeks before surgery, patients should have a chest CT for COVID-19 screening and routine blood assay, C-reactive protein, procalcitonin, and influenza A and B examination within 1 week. If infection is suspected, a further upper nasopharyngeal swab test for COVID-19 should be performed. In fact, all patients should undergo a swab test before surgery. Postoperative fever, shortness of breath, and cough are common clinical manifestations for surgical patients. Fever can be caused by postoperative absorption and bacterial pneumonia of the respiratory tract or pleural infection. Postoperative chest tightness and shortness of breath are also common, due to bacterial pneumonia, atelectasis, and acute respiratory distress syndrome. Rare causes include pulmonary embolism, pulmonary volvulus, interstitial pneumonia, and bronchopleural fistula. These cases should be identified carefully and differentiated in a timely manner. In addition, because of symptom overlap with COVID-19 infection, these conditions should be differentiated from COVID-19. In the context of the current COVID-19 pandemic, thoracic surgeons should avoid surgery for benign tumors. Even for malignancies, strict control of the indications for operations is recommended, comprehensive treatment should be emphasized, and alternative treatment strategies should be implemented to avoid COVID-19 infection in hospital and ensure medical safety and quality. The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. Commentary: Thoracic surgery during the COVID-19 pandemic: Recommendations from ChinaThe Journal of Thoracic and Cardiovascular SurgeryVol. 160Issue 4PreviewAt the time of this writing, COVID-19 continues to surge in the United States, with more than 5.1 million cases and 165,000 deaths nationwide.1 Guidelines from the United States and Europe have been published to aid treatment decision making for thoracic cancers during the pandemic.2-15 Most of these guidelines have been written for hospitals and clinicians who still have the capacity to take care of cancer patients and have not been completely overwhelmed by COVID-19. These guidelines have generally recommended delaying surgery for select instances of early-stage disease and, for more advanced disease, proceeding with traditional curative-intent treatment consistent with pre-COVID standard-of-care recommendations. Full-Text PDF Open ArchiveCommentary: Collaboration is key to saving as many lives as possibleThe Journal of Thoracic and Cardiovascular SurgeryVol. 160Issue 4PreviewIn the August 2020 issue of the Journal, Chen and colleagues1 share insights from the Chinese experience with Coronavirus Disease 2019 (COVID-19) for the benefit of improving thoracic surgical outcomes worldwide during this unprecedented time. This article is certainly timely, and at this moment, the information shared is likely of greater relevance to the majority of surgeons in our field than any other previous publication. This pandemic affects us all—all of our practices, all of our patients, all of our colleagues and communities. Full-Text PDF Open Archive

Commentary: Exquisite Surgical Techniques and Comprehensive Oncologic Theory Are Two Fundamental Requirements of Learning Lung Cancer Surgery.

Commentary: the Debate Between Surgery and Stereotactic Body Radiation Therapy in Treatment of Early Non–small Cell Lung Cancer: A New Connotation is Needed for an Old Topic

Therapeutic strategy for lung adenocarcinoma with pure ground-glass opacity: surgery, radiotherapy, or watchful waiting?

Do Not Go Too Far when Choosing Intentional Segmentectomy for Small-Sized Lung Cancers

Segmentectomy for NSCLC: a Better Alternative?

Commentary: is Segmentectomy Ready to Be Accepted As the Standard of Care?

Potential Benefited Population for Sublobar Resection

Minimally Invasive Thoracic Surgery 3.0

Lymph node dissection in lung cancer surgery

Thoracic Surgeons' Insights: Improving Thoracic Surgery Outcomes During the Coronavirus Disease 2019 Pandemic.

Commentary: Anatomical Partial Lobectomy: the Indications Should Be Better Defined.

Pure ground-glass opacities (GGO) lung adenocarcinoma: surgical resection is curative

Surgical Treatment of Early l Stage Lung Cancer: What has Changed and What will Change in the Future

Identifiable and Unidentifiable Factors Influencing Lymph Node Examination and Adjuvant Chemotherapy in Stage I Lung Cancer

Clinical Study of Surgical Treatment of Non-small Cell Lung Cancer 10 Mm or Less in Diameter under Video-assisted Thoracoscopy

The IASLC/ATS/ERS Classification of Lung Adenocarcinoma-a Surgical Point of View.

Sublobar Resection for Lung Adenocarcinoma Less Than 2 Cm Containing Solid or Micropapillary Components Radiologically Presented As Consolidation-to-tumor Ratio (CTR) ≤0.25 [Ground-Glass Opacity (GGO)]

Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective

Performing High-Quality Sublobar Resections: Key Differences Between Wedge Resection and Segmentectomy

Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller